Cibus Prices Public Offering of 13.33 Million Shares at $1.50 Each
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9h ago
0mins
Cibus announced the pricing of an underwritten public offering of 13,333,333 shares of its Class A Common Stock, par value $0.0001 per share, at a public offering price of $1.50 per share. Members of Cibus' Board of Directors will purchase 1,000,000 shares of Class A Common Stock in the Offering at the public offering price. The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,999,999 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the Offering are to be sold by the Company. The gross proceeds of the Offering will be approximately $20M before deducting underwriting discounts and commissions in the Offering and other estimated expenses payable by the Company. The Offering is expected to close on January 30, 2026, subject to the satisfaction of customary closing conditions. BTIG is acting as the sole underwriter for the Offering.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on CBUS
Wall Street analysts forecast CBUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBUS is 18.67 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.760
Low
15.00
Averages
18.67
High
25.00
Current: 1.760
Low
15.00
Averages
18.67
High
25.00
About CBUS
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cibus and Interoc Sign LOI for 2027 Market Entry in Latin America
- Market Entry Plan: Cibus and Interoc have signed a non-binding Letter of Intent (LOI) to initiate commercialization in Ecuador and Colombia by 2027, followed by expansion into Peru, Central America, and the Caribbean, marking a significant shift from R&D to market execution in their collaboration.
- Technology Integration: Cibus has successfully integrated herbicide-tolerant traits into Interoc's elite rice germplasm, which is expected to enhance productivity in Latin America by addressing urgent farmer needs against resistant weeds, thereby improving yields.
- Collaboration Potential: The signing of the LOI establishes a framework for commercial sales, with Cibus and Interoc aiming to jointly promote high-performing rice hybrids in key markets, targeting rapid market share growth in rice production areas.
- Sustainable Development Goals: By combining Cibus' gene-editing technologies with Interoc's elite genetics, both companies are committed to enhancing agricultural productivity and advancing sustainable farming practices in Latin America to meet the increasing food demand.
Continue Reading
Cibus Advances Gene Editing Legislation in EU for Enhanced Plant Breeding
- Legislative Progress: Cibus welcomes the agreement on the EU's New Genomic Techniques (NGTs) regulatory framework, marking a significant advancement in the company's efforts to innovate gene-edited plants, which is expected to provide European farmers with improved crop varieties.
- Market Opportunities: This agreement offers Cibus legal assurance to develop new plant varieties in the European market, likely driving growth in the company's market share within the agricultural technology sector to meet increasing agricultural demands.
- International Collaboration: Cibus has successfully completed field trials in the UK for its advanced trait in winter oilseed rape, demonstrating the company's leadership in gene editing technology and further enhancing its competitive edge in the European market.
- Strategic Investment: Cibus's technology development aligns with the EU's legislative process, which is expected to create new growth opportunities for the company's product pipeline, particularly in addressing pressing agricultural challenges.
Continue Reading